WWW.DISSERS.RU


...
    !

Pages:     | 1 | 2 ||

plasa hoocyst (e) ine should be treated Effects of vitain Hyperhoocysteineia but not the C677 T utation of MTHFR therapy on progression of carotid atherosclerosis in patients is an independent risk deterinant of carotid wall thickening // with hoocyst (e) ine levels above and below 14 icrool L // Circulation. 1999. Vol. 99. P. 23832388.

Aer. J. Hypertens. 2000. Vol. 13. P. 105110.

13. Li H. Hoocysteine induces 3-hydroxy-3-ethilglutaril 37. Konings E. J. Dietary folates in huan nutrition: thesis coenzye a reductase in vascular endothelial cells: A echanis University of Maastricht, The Neterlands, 2001. P. 105120.

for developent of atherosclerosis // Circulation. 2002. Vol. 105.

38. The increase of plasa hoocysteine concentrations P.10371042.

with age is partly due to the deterioration of renal function as 14. Hoocysteine induces 3-hydroxy-3-ethylglutaryl deterined by plasa cystatin / L. Norlund, A. Grubb, G. Fex [et coenzye A reductase in vascular endothelial cells / . Li, . Lewis, al.] // Lab. Med. 1998. Vol. 36. P. 175178.

S. Brodsky [et al.] // Circulation, 2002 Vol. 105. P. 10371043.

39. Coffee consuption and plasa total hoocysteine:

15. Plasa hoocysteine concentretion, statin therapy, the Hordaland Hoocysteine study / O. Nygard, H. Refsu, and the risk of first acute coronary eventsker / P. M. Rid, J. Shih, P. M. Ueland [et al.] // A. J. Clin. Nutr. 1997. Vol. 65. P. 136T. J. Cook [et al.] // Circulation. 2002. Vol. 105. P. 17761779.

40. Refsu H., Ueland P. M. Clinical significance of 16. Lang D., Kredan M. B., Lang D., Moat S. J. Hoocysteine pharacological odulation of hoocysteine etabolis // induced inhibition of endotheliu-dependent relaxation in rabbit Trends Pharacol Sci. 1990. Vol. 11. P. 411416.

aorta Role for superoxide anions // Arterioscler. Throb. Vasc.

41. Schneede J., Refsu H., Ueland P. M. Biological and Biol. 2000. P. 367373.

environental deterinants of plasa hoocysteine // Sein.

17. Uel P. M., Refsu H. Plasa hoocysteine, a risk factor Throb. Heost. 2000. Vol. 26. P. 263279.

for vascular disease plasa levels in health, disease, and drug 42. Decreased rate of coronary restenosis after lowering of therapy // ed. 1989. . 114501.

plasa hoocysteine levels / G. Schnyder, M. Roffi, R. Pin [et al.] 18. The effect of horone replaceent therapy on seru //N. Engl. J. Med. 2001. Vol. 345. P. 15931600.

hoocysteine levels in perienopausal woen: a randoized 43. Elevated plasa concentrations of hoo-cysteine controlled study / E. Hak, A. Bak, J. Lindeans [et al.] // in antiepileptic drug treatent / M. Schwaninger, P. Ringleb, Atherosclerosis, 2001. Vol. 158. P. 437439.

R. Winter // Epilepsia.1999. Vol. 40. P. 345350.

19. Hansrani M. Hoocysteine in yointial hyperplasia // 44. The effect of a subnoral vitain B-6 status on Vasc Endovasc Surg. 2002. Vol. 23. P. 310.

hoocysteine etabolis / J. B. Ubbink, R. Delport, R. H. Allen 20. Harker L., Ross R., Slichter S., Scott C. Hoocysteineia:

[et al.] // J. Clin. Investig. 1996. Vol. 98. P.177184.

vascular injury and arterial throbosis // N. Engl. J. Med. 1974.

45. Ueland P. M., Refsu H. Plasa hoocysteine, a risk Vol. 291. P. 537543.

factor for vascular disease: plasa levels in health, disease and 21. Loscalo J. The oxidant stress of hyperhoocyst (e) drug therapy // J. Lab. Clin. Med. 1989. Vol. 114. P. 473ineia // J. Clin. Invest. 1996 Vol. 98. P. 57.

46. 5-ethyltetrahydrofolate, the active for of folic acid, 22. Wotherspoon F., Laight D., Shaw K., Curestores endothelial function in failial hypercholesteroleia / ings M. Hoocysteine, endothelial dysfunction and oxidative M. C. Verhaar, R. M. Wever, J. J. Kastelein [et al.] // Circulation.

stress in type 1 diabetes ellitus // Br. J. Diabetes Vasc. Dis.

1998. Vol. 97. P. 237241.

2003. Vol. 3. P. 334340.

47. Effects of oral folic acid suppleentation on endothelial 23. . ., . . function in failial hypercholesteroleia: A randoized ( ) // placeboFcontrolled trial / M. C. Verhaar, R. M. Wever, . 2004. 10. C. 8587.

J. J. Kastelein [et al.] // Circulation. 1999. Vol. 100. P. 335338.

24. . . 48. Norohoocysteinaeia and vitainFtreated // . 2000. 6. C. 6165.

hyperhoocysteinaeia are associated with siilar risks of 25. . ., . ., . . cardiovascular events in patients with preature atherothrobotic cerebrovascular disease / E. G. Vereulen, J. A. Rauwerda, // P. Erix [et al.] // A prospective cohort study. Neth. J. Med. 2000.

/ 2002. 1. C. 6571.

Vol. 56. P. 138146.

26. . ., . . // .

References . 1999. 2. C. 4448.

27. . . 1. McCully K. S. Vascular pathology of hoocysteineia:

// . 2004. iplications for the pathogenesis of atherosclerosis // 1. C. 6973. Aer. J. Pathol. 1969. Vol. 56. P. 111128.

Saratov Journal of Medical Scientific Research. 2011. Vol. 7, 3.

624 2. Stapfer M. Can lowering hoocysteine levels reduce 27. Lysenko M.Je. Korrekcija gipergoocisteineii u bolnyh cardiovascular risk // Engl. J. Med. 1995. . 328332. IBS // Ukrainskij terapevticheskij zhurnal. 2004. 1. C. 6973.

3. Mayer E., Jacobsen D., Robinson . Hoocysteine and 28. Muhin N.A., Moiseev S.V., Foin V.V.

coronary atherosclerosis // J. A Coll Cardiol.. 1996. . 517527.

Gipergoocisteineija kak faktor riska razvitija zabolevanij 4. Hankey G. J. Hoocysteine and vascular disease // serdechno-sosudistoj sistey // Klinicheskaja edicina. 2001.

Lancet. 1999. Vol. 354. P. 407413.

6. s. 75. MacMahon M., Kirkpatrick C. Nutr Metab Cardiovasc // 29. Shevchenko O.P., Olefrienko G.A. Gipergoocisteineija Dis. 2000. Vol. 10. 195203.

i ee klinicheskoe znachenie // Laboratorija. 2002. 1. C. 37.

6. Hoocysteine and short ter risk of yocardial infarction 30. Sheleva V.M. Gipergoocisteineija i troboz // and stroke in the elderly / . Bots, L. Launer, J. Lindeans [et al.] Troboz, geostaz i reologija. 2000. 4. C. 2629.

// The Rotterda Study Arch. Intern. Med. 1999. . 138159.

31. Hubutija M.Sh., Shevchenko O.P. Goocistein pri 7. Bonitton-Kopp. . Early carotid atherosclerosis in healthy koronarnoj bolezni serdca i serdechnogo transplantanta. M.:

iddle-aged woen // Kopp. Ibid, 1993. Vol. 24. P 18371843.

Refar, 2004. 272 s. 32. Arnadottir M. Hoocysteine in renal 8. Single LDL apheresis iproves endotheliu dependent disease, in Hoocysteine in health and disease // Cabridge vasodilatation in hypercholesteroleic huans / O. Taai, University Press, Cabridge, UK, 2001. P. 321330.

H. Matsuoka, H. Itabe [et al.] // Circulation. 1997. Vol. 95. P. 7682.

33. Plasa hoocysteine in woen on oral oestrogen9. For the West of Scotland Coronary Prevention Study Group containing contraceptives and in en with oestrogen-treated Prevention of coronary heart disease with pravastatin in en with prostatic carcinoa / L. Brattstro, B. Israelsson, A. Olsson [et hypercholesteroleia / J. Shepherd, S. M. Cobbe, I. Ford [et al.] // al.] // Scand. J. Clin. Lab. Investig. 2001. Vol. 52. P. 283N. Engl. J. Med. 1995. Vol. 333. P. 13011307.

34. Lowering blood hoocysteine with folic acid based 10. Engl N. The Long-Ter Intervention with Pravastatin suppleents: eta-analysis of randoised trials / L. Brattstro, in Ischaeic Disease (LIPID) Study Group. Prevention of F. Landgren, B. Israelsson [et al.] // Br. Med. J. 1998. Vol. 316.

cardiovascular events and death with Pravastatin in patients with P. 894898.

coronary heart disease and a broad range of initial cholesterol levels // J. Med. 1998. Vol. 339. P. 13491357. 35. Unfiltered coffee increases plasa hoocysteine 11. Effect of pravastatin on endothelial function in patients with concentrations in healthy volunteers: a randoized coronary artery disease / A. Masuoto, Y. Hirooka, K. Hironaga trial / M. J. Grubben, G. H. Boers, H. J. Blo [et al.] // A. J. Clin.

[et al.] // Aer. J. Cardiol, 2001. Vol. 88. P. 12911294.

Nutr. 2000. Vol. 71. P. 480484.

12. McQuillan B. M., Beilby J. P., Nidorf P. L. Thopson.

36. Hacka D. G., Peterson J. C., Spence J. D. What level of Hyperhoocysteineia but not the C677 T utation of MTHFR plasa hoocyst (e) ine should be treated Effects of vitain is an independent risk deterinant of carotid wall thickening // therapy on progression of carotid atherosclerosis in patients Circulation. 1999. Vol. 99. P. 23832388.

with hoocyst (e) ine levels above and below 14 icrool L // 13. Li H. Hoocysteine induces 3-hydroxy-3-ethilglutaril Aer. J. Hypertens. 2000. Vol. 13. P. 105110.

coenzye a reductase in vascular endothelial cells: A echanis 37. Konings E. J. Dietary folates in huan nutrition: thesis for developent of atherosclerosis // Circulation. 2002. Vol. 105.

University of Maastricht, The Neterlands, 2001. P. 105120.

P.10371042.

38. The increase of plasa hoocysteine concentrations 14. Hoocysteine induces 3-hydroxy-3-ethylglutaryl with age is partly due to the deterioration of renal function as coenzye A reductase in vascular endothelial cells / . Li, . Lewis, deterined by plasa cystatin / L. Norlund, A. Grubb, G. Fex [et S. Brodsky [et al.] // Circulation, 2002 Vol. 105. P. 10371043.

al.] // Lab. Med. 1998. Vol. 36. P. 175178.

15. Plasa hoocysteine concentretion, statin therapy, 39. Coffee consuption and plasa total hoocysteine:

and the risk of first acute coronary eventsker / P. M. Rid, J. Shih, the Hordaland Hoocysteine study / O. Nygard, H. Refsu, T. J. Cook [et al.] // Circulation. 2002. Vol. 105. P. 17761779.

P. M. Ueland [et al.] // A. J. Clin. Nutr. 1997. Vol. 65. P. 13616. Lang D., Kredan M. B., Lang D., Moat S. J. Hoocysteine 40. Refsu H., Ueland P. M. Clinical significance of induced inhibition of endotheliu-dependent relaxation in rabbit pharacological odulation of hoocysteine etabolis // aorta Role for superoxide anions // Arterioscler. Throb. Vasc.

Trends Pharacol Sci. 1990. Vol. 11. P. 411416.

Biol. 2000. P. 367373.

41. Schneede J., Refsu H., Ueland P. M. Biological and 17. Uel P. M., Refsu H. Plasa hoocysteine, a risk factor environental deterinants of plasa hoocysteine // Sein.

for vascular disease plasa levels in health, disease, and drug Throb. Heost. 2000. Vol. 26. P. 263279.

therapy // ed. 1989. . 114501.

18. The effect of horone replaceent therapy on seru 42. Decreased rate of coronary restenosis after lowering of hoocysteine levels in perienopausal woen: a randoized plasa hoocysteine levels / G. Schnyder, M. Roffi, R. Pin [et al.] controlled study / E. Hak, A. Bak, J. Lindeans [et al.] // //N. Engl. J. Med. 2001. Vol. 345. P. 15931600.

Atherosclerosis, 2001. Vol. 158. P. 437439.

43. Elevated plasa concentrations of hoo-cysteine 19. Hansrani M. Hoocysteine in yointial hyperplasia // in antiepileptic drug treatent / M. Schwaninger, P. Ringleb, Vasc Endovasc Surg. 2002. Vol. 23. P. 310.

R. Winter // Epilepsia.1999. Vol. 40. P. 345350.

20. Harker L., Ross R., Slichter S., Scott C. Hoocysteineia:

44. The effect of a subnoral vitain B-6 status on vascular injury and arterial throbosis // N. Engl. J. Med. 1974.

hoocysteine etabolis / J. B. Ubbink, R. Delport, R. H. Allen Vol. 291. P. 537543.

[et al.] // J. Clin. Investig. 1996. Vol. 98. P.177184.

21. Loscalo J. The oxidant stress of hyperhoocyst (e) 45. Ueland P. M., Refsu H. Plasa hoocysteine, a risk ineia // J. Clin. Invest. 1996 Vol. 98. P. 57.

factor for vascular disease: plasa levels in health, disease and 22. Wotherspoon F., Laight D., Shaw K., drug therapy // J. Lab. Clin. Med. 1989. Vol. 114. P. 473Cuings M. Hoocysteine, endothelial dysfunction and 46. 5-ethyltetrahydrofolate, the active for of folic acid, oxidative stress in type 1 diabetes ellitus // Br. J. Diabetes Vasc.

restores endothelial function in failial hypercholesteroleia / Dis. 2003. Vol. 3. P. 334340.

M. C. Verhaar, R. M. Wever, J. J. Kastelein [et al.] // Circulation.

23. Baranova E.I., Bolshakova O.O. Klinicheskoe znachenie 1998. Vol. 97. P. 237241.

goocisteineii (obzor literatury) // Arterialnaja gipertenzija.

47. Effects of oral folic acid suppleentation on endothelial 2004. 10. C. 8587.

function in failial hypercholesteroleia: A randoized 24. Barkagan Z.S. Uchenie o trobofilijah na sovreenno placeboFcontrolled trial / M. C. Verhaar, R. M. Wever, J. J. Kastejetape // Konsiliu. 2000. 6. C. 6165.

lein [et al.] // Circulation. 1999. Vol. 100. P. 335338.

25. Barkagan Z.S., Kostjuchenko G.I., Kotovwikova E.F.

48. Norohoocysteinaeia and vitainFtreated hyperhoGipergoocisteineija kak saostojatelnyj faktor riska ocysteinaeia are associated with siilar risks of cardiovasporazhenija i trobirovanija krovenosnyh sosudov // Patologija cular events in patients with preature atherothrobotic cerekrovoobrawenija i kardiohirurgija / 2002. 1. C. 6571.

brovascular disease / E. G. Vereulen, J. A. Rauwerda, P. Erix 26. Cakalov A.K., Efiov V.S. Goocisteineija v patogeneze trobovaskuljarnoj bolezni i ateroskleroza // Lab. [et al.] // A prospective cohort study. Neth. J. Med. 2000. Vol. 56.

ed. 1999. 2. C. 4448. P. 138146.

- . 2011. . 7, 3.

Pages:     | 1 | 2 ||



2011 www.dissers.ru -

, .
, , , , 1-2 .